Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Vertex Pharmaceuticals    VRTX

VERTEX PHARMACEUTICALS

(VRTX)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths
  • Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
  • Based on current prices, the company has particularly high valuation levels.
  • With an expected P/E ratio at 52.94 and 37.75 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
Ratings chart
Sector Bio Therapeutic Drugs
1st jan.Capitalisation (M$)Investor Rating
VERTEX PHARMACEUTICALS7.49%45 783
GILEAD SCIENCES6.19%84 118
REGENERON PHARMACEUTICALS-20.78%32 375
GENMAB31.33%13 425
NEUROCRINE BIOSCIENCES, INC..41.20%9 234
HUALAN BIOLOGICAL ENGINEERI..--.--%6 523
SAREPTA THERAPEUTICS INC-24.39%6 134
EXELIXIS, INC.-0.56%5 925
BLUEBIRD BIO INC7.67%5 903
TONGHUA DONGBAO PHARMACEUTI..35.83%5 415
ASCENDIS PHARMA A/S74.76%5 206
CHINA BIOLOGIC PRODUCTS HOL..50.44%4 370
SPARK THERAPEUTICS INC161.52%3 939
BIOCON LTD-27.49%3 796
MIRATI THERAPEUTICS INC120.27%3 672
IDORSIA LTD60.91%3 448
More Results
Financials (USD)
Sales 2019 3 700 M
EBIT 2019 1 554 M
Net income 2019 875 M
Finance 2019 3 460 M
Yield 2019 -
P/E ratio 2019 52,9x
P/E ratio 2020 37,8x
EV / Sales2019 11,4x
EV / Sales2020 9,10x
Capitalization 45 783 M
Upcoming event on VERTEX PHARMACEUTICALS
Surperformance© ratings
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes